In human CD4+ T-Cells, omeprazole suppresses proliferation, downregulates V-ATPase, and promotes differentiation toward an autoimmunity-favoring phenotype
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2024.113728 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Georgios Pissas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Faculty of Medicine, University of Thessaly, Larissa, Greece. Hauptthemen laut MEDLINE: Omeprazole, Cell Differentiation, Cell Proliferation, Proton Pump Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Proton pump inhibitors (PPIs) represent a commonly prescribed class of medications. Triggered by findings indicating a correlation between PPI usage and susceptibility to infectious or autoimmune diseases, we studied the impact of a pharmacological concentration of omeprazole on human CD4+ T-cells. METHODS: In mixed lymphocyte reactions (MLRs), we analyzed the proliferation index and measured the concentration of key cytokines representative of distinct CD4+ T-cell subsets. In CD4+ T-cells isolated from the MLRs, we evaluated proliferation markers and pathways, the expression of signature transcription factors of CD4+ T-cell subsets, vacuolar H+- ATPase (V-ATPase) levels, and the activation status of AMP-activated kinase (AMPK) and mammalian target of rapamycin complex-1 (mTORC1). RESULTS: Omeprazole reduced proliferation index in MLRs, and in isolated CD4+ T-cells, it downregulated the proliferation marker Ki-67, possibly mediated by the p53- p21 pathway. Analysis of cytokines and signature transcription factors of CD4+ T-cell subsets indicated that omeprazole decreased T helper 1 (Th1) differentiation, had negligible impact on Th2 differentiation, increased Th17 differentiation, and reduced regulatory T-cell (Treg) differentiation. Omeprazole also decreased V-ATPase, a known target of PPIs and a site for AMPK and mTORC1 activation. Consequently, this led to diminished activation of these kinases, potentially elucidating the mechanism by which omeprazole influences CD4+ T-cell differentiation. CONCLUSION: Omeprazole downregulates V-ATPase and inhibits activation of AMPK and mTORC1. As a result, omeprazole suppresses CD4+ T-cell clonal expansion, potentially contributing to the observed association between PPIs and susceptibility to infections. Additionally, it modulates CD4+ T-cell differentiation in a manner that favors autoimmunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
- Department of Nephrology, Faculty of Medicine, University of Thessaly, Larissa, Greece. Electronic address: teleftheriadis@yahoo.com.
Zitieren
APA
Pissas, G., Tziastoudi, M., Poulianiti, C., Polyzou Konsta, M. A., Lykotsetas, E., Liakopoulos, V., Stefanidis, I., & Eleftheriadis, T. (2025). In human CD4+ T-Cells, omeprazole suppresses proliferation, downregulates V-ATPase, and promotes differentiation toward an autoimmunity-favoring phenotype. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113728
Vancouver
Pissas G, Tziastoudi M, Poulianiti C, Polyzou Konsta MA, Lykotsetas E, Liakopoulos V, et al. In human CD4+ T-Cells, omeprazole suppresses proliferation, downregulates V-ATPase, and promotes differentiation toward an autoimmunity-favoring phenotype. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113728
BibTeX
@article{Pissas2025,
author = {Pissas, Georgios and Tziastoudi, Maria and Poulianiti, Christina and Polyzou Konsta, Maria Anna and Lykotsetas, Evangelos and Liakopoulos, Vasilios and Stefanidis, Ioannis and Eleftheriadis, Theodoros},
title = {In human CD4+ T-Cells, omeprazole suppresses proliferation, downregulates V-ATPase, and promotes differentiation toward an autoimmunity-favoring phenotype},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2024.113728}
}
EUVIMED